The current bivalent cervical cancer vaccine lasts at least 10 years, but there are some individual differences. Depending on how many types of virus subtypes are covered by the vaccine cervical cancer vaccines can be categorized as bivalent, quadrivalent, and nivalent. The bivalent vaccine targets high-risk HPV (human papillomavirus) types 16 and 18. The bivalent vaccine produces antibodies that provide long-term protection, and the vaccine is currently effective for at least 10 years. A study of a 10-year follow-up period after vaccination No. 1 found that antibodies remained largely unchanged after vaccination, with some individual variation. The appropriate age for the bivalent vaccine is 9 to 45 years. The bivalent vaccine is suitable for both women who are not sexually active and for preventing HPV infection in women who are sexually active and may be infected with HPV. The cervical cancer vaccine cannot achieve 100% protection, so regular review is still needed after vaccination to avoid delaying the disease.